Bausch Health Companies (BHC) Expected to Announce Quarterly Earnings on Thursday

Bausch Health Companies (NYSE:BHC) is expected to be releasing its earnings data before the market opens on Thursday, February 27th. Analysts expect Bausch Health Companies to post earnings of $1.12 per share for the quarter. Bausch Health Companies has set its FY 2025 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Bausch Health Companies Stock Performance

Bausch Health Companies stock opened at $6.54 on Thursday. The firm’s 50 day moving average price is $7.37 and its two-hundred day moving average price is $7.47. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of -13.63, a price-to-earnings-growth ratio of 0.32 and a beta of 0.68.

Analyst Ratings Changes

A number of research firms have recently weighed in on BHC. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Royal Bank of Canada cut their price objective on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research report on Thursday, January 30th. Finally, StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.